Chronic Stable Angina

To the Editor: In his Clinical Practice article (June 16 issue), 1 Abrams suggests that a 24-hour interval is warranted between the use of the phosphodiesterase inhibitors sildenafil, vardenafil, and tadalafil and the use of nitrates to prevent serious hypotension. However, Kloner 2 differentiates a...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 353; no. 14; p. 1524
Main Authors Aguiar-Souto, Pablo, Silva-Melchor, Lorenzo, Ortigosa-Aso, Francisco J
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 06.10.2005
Subjects
Acetanilides
Angina Pectoris - drug therapy
Chronic Disease
Drug Interactions
Enzyme Inhibitors - therapeutic use
Humans
Hypotension - chemically induced
Nitrates - adverse effects
Nitrates - therapeutic use
Phosphodiesterase Inhibitors - adverse effects
Piperazines - therapeutic use
Ranolazine
Time Factors
Online AccessGet full text

Cover

More Information
Summary:To the Editor: In his Clinical Practice article (June 16 issue), 1 Abrams suggests that a 24-hour interval is warranted between the use of the phosphodiesterase inhibitors sildenafil, vardenafil, and tadalafil and the use of nitrates to prevent serious hypotension. However, Kloner 2 differentiates among agents, recommending a 24-hour interval in the case of sildenafil or vardenafil, but at least 48 hours in the case of tadalafil. 3 Under the heading “Areas of Uncertainty,” Abrams questioned the role of ranolazine in the treatment of stable angina. There are at least two trials in which ranolazine is evaluated in this setting. In the Monotherapy . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc051901